Pasithea Therapeutics Corp. (KTTA) Stock

Pasithea Therapeutics Corp. is a dynamic biotechnology firm specializing in pioneering treatments for psychiatric and neurological disorders through advanced research and discovery initiatives. Additionally, the company plans to establish and manage anti-depression clinics, offering specialized support services that include intravenous infusions of ketamine administered by trained pharmacists. This innovative approach underscores Pasithea Therapeutics' commitment to enhancing mental health care by leveraging cutting-edge therapies.

Founded in 2020 and based in Miami Beach, Florida, Pasithea Therapeutics is at the forefront of addressing critical gaps in psychiatric and neurological treatments. With a focus on developing novel therapies and expanding clinical services, the company aims to significantly impact the lives of patients affected by these challenging conditions. Pasithea Therapeutics continues to drive forward with a vision of advancing mental health care through innovation and compassionate patient support.

In addition to its research and clinical initiatives, Pasithea Therapeutics Corp. is dedicated to fostering partnerships and collaborations within the healthcare community. By leveraging expertise and resources, the company seeks to accelerate the development and delivery of transformative therapies that meet the diverse needs of individuals suffering from psychiatric and neurological disorders.